{"hands_on_practices": [{"introduction": "A primary challenge in producing bispecific antibodies (BsAbs) is ensuring the correct pairing of two distinct heavy chains. This exercise addresses this fundamental manufacturing problem by modeling the 'Knobs-into-Holes' technology, a widely used strategy to promote heterodimerization. By working through this problem [@problem_id:5012011], you will connect molecular design principles to practical bioprocessing outcomes, learning to predict the initial purity of a BsAb batch and determine the purification stringency required to achieve a therapeutic-grade product.", "problem": "A biotechnology team is engineering bispecific Immunoglobulin G (IgG) by co-expressing two different heavy chains, denoted $A$ and $B$, modified with the Knobs-into-Holes (KH) interface to favor heterodimerization. In the Endoplasmic Reticulum (ER), heavy-chain dimerization is modeled as three competing second-order association processes: $A + A \\to AA$, $B + B \\to BB$, and $A + B \\to AB$, with effective second-order rate constants $k_{AA}$, $k_{BB}$, and $k_{AB}$, respectively. Assume $k_{AA} = k_{BB} = k_{H}$ due to symmetric residual homodimerization propensity in the KH design, and that pairing is irreversible over the relevant timescale (so product fractions are proportional to formation propensities).\n\nThe team has measured the KH heterodimerization efficiency under equimolar heavy-chain co-expression, defined as the fraction of $AB$ dimers among all dimers formed at $[A] = [B]$, yielding $p_{KH} = 0.94$. In the production cell line, the heavy-chain expression ratio is imbalanced, with $[A]:[B] = 1.20:1$. The fraction of correctly formed heterodimers in the crude product is $f_{AB}$, computed as the ratio of the $AB$ formation propensity to the sum of all formation propensities. Downstream, a single idealized purification step is planned that perfectly retains $AB$ and uniformly reduces both homodimers ($AA$ and $BB$) by the same fold-reduction factor $F$. The target final purity of $AB$ is $P = 0.98$ (expressed as a decimal fraction).\n\nStarting only from the law of mass action and the given definitions and measurements, derive an expression for $f_{AB}$ in terms of $p_{KH}$ and the expression ratio $r = [A]/[B]$, then evaluate $f_{AB}$ numerically for $p_{KH} = 0.94$ and $r = 1.20$. Next, derive and evaluate the minimal $F$ required to achieve the final purity $P = 0.98$ from the crude $f_{AB}$. Round both the expected fraction $f_{AB}$ and the required fold-reduction $F$ to four significant figures. Express both final quantities as pure numbers without units.", "solution": "The problem asks for the derivation and calculation of the crude heterodimer fraction, $f_{AB}$, and the required purification fold-reduction factor, $F$, for the production of a bispecific antibody. The solution is grounded in the principles of chemical kinetics, specifically the law of mass action for competing reactions.\n\nFirst, we formalize the dimerization process. The formation of the three dimer species, $AA$, $BB$, and $AB$, from heavy chains $A$ and $B$ are described as second-order reactions. Their rates of formation ($V$) are given by:\n$$ V_{AA} = k_{AA} [A]^2 $$\n$$ V_{BB} = k_{BB} [B]^2 $$\n$$ V_{AB} = k_{AB} [A][B] $$\nwhere $[A]$ and $[B]$ are the concentrations of the respective heavy chains, and $k_{AA}$, $k_{BB}$, and $k_{AB}$ are the second-order rate constants.\n\nThe problem states that the Knobs-into-Holes (KH) design leads to a symmetric residual homodimerization propensity, so we can set $k_{AA} = k_{BB} = k_{H}$. The rates are then:\n$$ V_{AA} = k_{H} [A]^2 $$\n$$ V_{BB} = k_{H} [B]^2 $$\n$$ V_{AB} = k_{AB} [A][B] $$\n\nThe problem also states that the fraction of each product formed is proportional to its formation propensity (rate). The fraction of the desired heterodimer, $f_{AB}$, is therefore the ratio of its formation rate to the sum of all formation rates:\n$$ f_{AB} = \\frac{V_{AB}}{V_{AA} + V_{BB} + V_{AB}} = \\frac{k_{AB} [A][B]}{k_{H} [A]^2 + k_{H} [B]^2 + k_{AB} [A][B]} $$\n\nTo proceed, we must relate the rate constants $k_{H}$ and $k_{AB}$ using the provided experimental data. The heterodimerization efficiency under equimolar co-expression, $p_{KH}$, is the value of $f_{AB}$ when $[A] = [B]$. Substituting $[A]=[B]$ into the expression for $f_{AB}$:\n$$ p_{KH} = \\frac{k_{AB} [A][A]}{k_{H} [A]^2 + k_{H} [A]^2 + k_{AB} [A][A]} = \\frac{k_{AB} [A]^2}{2k_{H} [A]^2 + k_{AB} [A]^2} $$\nThe term $[A]^2$ cancels out, yielding a relationship purely between the rate constants and $p_{KH}$:\n$$ p_{KH} = \\frac{k_{AB}}{2k_{H} + k_{AB}} $$\nWe rearrange this equation to find the ratio of the heterodimerization rate constant to the homodimerization rate constant, $\\frac{k_{AB}}{k_H}$:\n$$ p_{KH}(2k_{H} + k_{AB}) = k_{AB} $$\n$$ 2p_{KH}k_{H} = k_{AB} - p_{KH}k_{AB} = k_{AB}(1 - p_{KH}) $$\n$$ \\frac{k_{AB}}{k_{H}} = \\frac{2p_{KH}}{1 - p_{KH}} $$\nThis ratio quantifies the KH technology's effectiveness in promoting heterodimerization over homodimerization.\n\nNow, we derive the expression for $f_{AB}$ in terms of $p_{KH}$ and the expression ratio $r = [A]/[B]$. We return to the general expression for $f_{AB}$ and divide the numerator and denominator by $k_{H}[B]^2$:\n$$ f_{AB} = \\frac{\\frac{k_{AB}}{k_H} \\frac{[A]}{[B]}}{\\left(\\frac{[A]}{[B]}\\right)^2 + 1 + \\frac{k_{AB}}{k_H} \\frac{[A]}{[B]}} $$\nSubstituting $r = [A]/[B]$ and the expression for $\\frac{k_{AB}}{k_H}$:\n$$ f_{AB}(p_{KH}, r) = \\frac{\\left(\\frac{2p_{KH}}{1 - p_{KH}}\\right)r}{r^2 + 1 + \\left(\\frac{2p_{KH}}{1 - p_{KH}}\\right)r} $$\nTo simplify, we multiply the numerator and the denominator by $(1 - p_{KH})$:\n$$ f_{AB}(p_{KH}, r) = \\frac{2p_{KH}r}{(1 - p_{KH})(r^2 + 1) + 2p_{KH}r} $$\nThis is the required expression for $f_{AB}$.\n\nNext, we evaluate $f_{AB}$ for the given values $p_{KH} = 0.94$ and $r = 1.20$:\n$$ 1 - p_{KH} = 1 - 0.94 = 0.06 $$\n$$ r^2 + 1 = (1.20)^2 + 1 = 1.44 + 1 = 2.44 $$\n$$ 2p_{KH}r = 2 \\times 0.94 \\times 1.20 = 2.256 $$\nSubstituting these into the expression for $f_{AB}$:\n$$ f_{AB} = \\frac{2.256}{(0.06)(2.44) + 2.256} = \\frac{2.256}{0.1464 + 2.256} = \\frac{2.256}{2.4024} \\approx 0.9390609... $$\nRounding to four significant figures, the expected crude fraction of heterodimer is $f_{AB} \\approx 0.9391$.\n\nThe second part of the problem is to determine the minimal fold-reduction factor $F$ required to achieve a final purity $P = 0.98$. The initial amounts of the species in the crude product are proportional to their formation rates, so their fractions are $f_{AA}$, $f_{BB}$, and $f_{AB}$. The total fraction of homodimer impurity is $f_{AA} + f_{BB} = 1 - f_{AB}$.\nThe purification step retains all $AB$ heterodimers and reduces the amounts of both $AA$ and $BB$ homodimers by a factor $F$. Let the initial amounts of species be $N_{AB}$, $N_{AA}$, and $N_{BB}$. After purification, the amounts are $N'_{AB} = N_{AB}$, $N'_{AA} = N_{AA}/F$, and $N'_{BB} = N_{BB}/F$.\nThe final purity $P$ is the fraction of $AB$ in the purified mixture:\n$$ P = \\frac{N'_{AB}}{N'_{AA} + N'_{BB} + N'_{AB}} = \\frac{N_{AB}}{\\frac{N_{AA}}{F} + \\frac{N_{BB}}{F} + N_{AB}} = \\frac{N_{AB}}{\\frac{N_{AA} + N_{BB}}{F} + N_{AB}} $$\nTo express this in terms of fractions, we can divide the numerator and denominator by the total initial amount, $N_{total} = N_{AA} + N_{BB} + N_{AB}$:\n$$ P = \\frac{N_{AB}/N_{total}}{(N_{AA} + N_{BB})/(F \\cdot N_{total}) + N_{AB}/N_{total}} = \\frac{f_{AB}}{\\frac{f_{AA} + f_{BB}}{F} + f_{AB}} $$\nSubstituting $f_{AA} + f_{BB} = 1 - f_{AB}$:\n$$ P = \\frac{f_{AB}}{\\frac{1 - f_{AB}}{F} + f_{AB}} $$\nWe now solve this equation for $F$:\n$$ P \\left( \\frac{1 - f_{AB}}{F} + f_{AB} \\right) = f_{AB} $$\n$$ \\frac{P(1 - f_{AB})}{F} = f_{AB} - Pf_{AB} = f_{AB}(1 - P) $$\n$$ F = \\frac{P(1 - f_{AB})}{f_{AB}(1 - P)} $$\nThis is the derived expression for $F$.\n\nFinally, we evaluate $F$ using $P = 0.98$ and the previously calculated value of $f_{AB} = \\frac{2.256}{2.4024}$:\n$$ 1 - P = 1 - 0.98 = 0.02 $$\n$$ 1 - f_{AB} = 1 - \\frac{2.256}{2.4024} = \\frac{2.4024 - 2.256}{2.4024} = \\frac{0.1464}{2.4024} $$\nPlugging these into the formula for $F$:\n$$ F = \\frac{0.98 \\times (1 - f_{AB})}{f_{AB} \\times 0.02} = \\frac{0.98}{0.02} \\times \\frac{1 - f_{AB}}{f_{AB}} $$\n$$ F = 49 \\times \\frac{0.1464/2.4024}{2.256/2.4024} = 49 \\times \\frac{0.1464}{2.256} \\approx 49 \\times 0.0648936... \\approx 3.179787... $$\nRounding to four significant figures, the required fold-reduction factor is $F \\approx 3.180$.", "answer": "$$\\boxed{\\begin{pmatrix} 0.9391  3.180 \\end{pmatrix}}$$", "id": "5012011"}, {"introduction": "The therapeutic effect of many bispecific antibodies hinges on their ability to act as a molecular bridge, simultaneously engaging two different antigens. This practice grounds that mechanism in the fundamental principles of chemical equilibrium and the law of mass action. You will derive the classic receptor occupancy equation from scratch and use it to build a model for the probability of target bridging [@problem_id:5012130], gaining critical insight into how binding affinity ($K_D$) and drug concentration ($C$) collectively govern the antibody's primary function.", "problem": "A bispecific antibody (BsAb) is engineered to bind antigen $A$ with equilibrium dissociation constant $K_{D,A}$ and antigen $B$ with equilibrium dissociation constant $K_{D,B}$. Consider a well-mixed interstitial compartment in which the free BsAb concentration is maintained at $C$ (that is, ligand depletion by binding does not significantly change the free concentration). Assume monovalent, independent binding of each arm to its cognate antigen, no cooperativity or cross-arm interference, and rapid equilibrium relative to pharmacokinetics and cell trafficking. Let $\\theta_{i}$ denote the receptor occupancy for antigen $i \\in \\{A,B\\}$, defined as the fraction of antigen $i$ molecules bound by BsAb at equilibrium.\n\nUsing the law of mass action and the definition of the equilibrium dissociation constant $K_{D,i}$, derive the receptor occupancy $\\theta_{i}$ as a function of $C$ and $K_{D,i}$. Then, under the assumption that simultaneous engagement of both antigens on the same cell (cis-bridging) is limited by the independent probabilities of each arm being bound, derive the bridging probability $P_{\\text{bridge}}(C)$ in terms of $C$, $K_{D,A}$, and $K_{D,B}$.\n\nFor a BsAb with $K_{D,A} = 1.5\\,\\mathrm{nM}$ and $K_{D,B} = 30\\,\\mathrm{nM}$, determine the free BsAb concentration $C$ (expressed in $\\mathrm{nM}$) required to achieve a target cis-bridging probability $P_{\\text{bridge}} = 0.06$. Round your final reported $C$ to three significant figures. You may compute the individual occupancies at that $C$ to support your reasoning, but for grading purposes report only the concentration. In your reasoning, explain how differential occupancy between the two antigens influences the bridging probability within this model. Do not use any pre-stated receptor occupancy formulas; start from the definition of $K_{D,i}$ and fundamental mass-action principles.", "solution": "The fundamental base is the law of mass action and the definition of the equilibrium dissociation constant. For a single antigen $i \\in \\{A,B\\}$ and ligand (the bispecific antibody) $L$, consider the reversible reaction\n$$\nR_i + L \\rightleftharpoons R_i L,\n$$\nwhere $R_i$ is free antigen $i$ and $R_i L$ is the antigen–ligand complex. At equilibrium, the equilibrium dissociation constant is defined by\n$$\nK_{D,i} \\equiv \\frac{[R_i][L]}{[R_i L]}.\n$$\nLet $[R_i]_{\\text{T}} = [R_i] + [R_i L]$ denote the total concentration of antigen $i$. The receptor occupancy is defined as the fraction of antigen $i$ that is bound:\n$$\n\\theta_i \\equiv \\frac{[R_i L]}{[R_i]_{\\text{T}}}.\n$$\nWe solve for $\\theta_i$ in terms of the free ligand concentration $[L]$ and $K_{D,i}$. From the definition of $K_{D,i}$, we have $[R_i L] = \\frac{[R_i][L]}{K_{D,i}}$. Substituting $[R_i] = [R_i]_{\\text{T}} - [R_i L]$ gives\n$$\n[R_i L] = \\frac{\\left([R_i]_{\\text{T}} - [R_i L]\\right)[L]}{K_{D,i}}.\n$$\nRearrange to collect $[R_i L]$ terms:\n$$\n[R_i L]\\left(1 + \\frac{[L]}{K_{D,i}}\\right) = \\frac{[R_i]_{\\text{T}}[L]}{K_{D,i}}.\n$$\nThus\n$$\n[R_i L] = \\frac{[R_i]_{\\text{T}}[L]}{K_{D,i} + [L]}.\n$$\nDivide both sides by $[R_i]_{\\text{T}}$ to obtain the receptor occupancy:\n$$\n\\theta_i = \\frac{[R_i L]}{[R_i]_{\\text{T}}} = \\frac{[L]}{K_{D,i} + [L]}.\n$$\nUnder the problem’s assumption that the free ligand concentration is maintained at $C$, we identify $[L] = C$ and therefore\n$$\n\\theta_i(C) = \\frac{C}{K_{D,i} + C}.\n$$\n\nNext, we derive the cis-bridging probability. Under independence and no cooperativity, the probability that a single BsAb molecule has its $A$-arm engaged is $\\theta_A(C)$ and that its $B$-arm is engaged is $\\theta_B(C)$. The probability of simultaneous engagement on the same cell is then approximated by the product\n$$\nP_{\\text{bridge}}(C) = \\theta_A(C)\\,\\theta_B(C) = \\frac{C}{K_{D,A}+C}\\cdot \\frac{C}{K_{D,B}+C} = \\frac{C^{2}}{(K_{D,A}+C)(K_{D,B}+C)}.\n$$\n\nWe are asked to find $C$ such that $P_{\\text{bridge}}(C) = P_{0}$ with $P_{0} = 0.06$, $K_{D,A} = 1.5\\,\\mathrm{nM}$, and $K_{D,B} = 30\\,\\mathrm{nM}$. Symbolically, set\n$$\nP_{0} = \\frac{C^{2}}{(K_{D,A}+C)(K_{D,B}+C)}.\n$$\nMultiply both sides:\n$$\nP_{0}\\left(C^{2} + (K_{D,A}+K_{D,B})C + K_{D,A}K_{D,B}\\right) = C^{2}.\n$$\nRearrange into a quadratic in $C$:\n$$\n(P_{0}-1)C^{2} + P_{0}(K_{D,A}+K_{D,B})C + P_{0}K_{D,A}K_{D,B} = 0.\n$$\nMultiply by $-1$ to have a positive leading coefficient:\n$$\n(1-P_{0})C^{2} - P_{0}(K_{D,A}+K_{D,B})C - P_{0}K_{D,A}K_{D,B} = 0.\n$$\nApply the quadratic formula. With $a = 1 - P_{0}$, $b = -P_{0}(K_{D,A}+K_{D,B})$, and $c = -P_{0}K_{D,A}K_{D,B}$,\n$$\nC = \\frac{-b + \\sqrt{b^{2} - 4ac}}{2a} = \\frac{P_{0}(K_{D,A}+K_{D,B}) + \\sqrt{P_{0}^{2}(K_{D,A}+K_{D,B})^{2} + 4(1-P_{0})P_{0}K_{D,A}K_{D,B}}}{2(1-P_{0})}.\n$$\nWe select the positive root because $C$ must be nonnegative and the other root is negative for $0  P_{0}  1$.\n\nNow substitute the given values $K_{D,A} = 1.5\\,\\mathrm{nM}$, $K_{D,B} = 30\\,\\mathrm{nM}$, and $P_{0} = 0.06$ to compute a numerical value for $C$ in $\\mathrm{nM}$:\n$$\nK_{D,A} + K_{D,B} = 31.5,\\quad K_{D,A}K_{D,B} = 45,\\quad 1 - P_{0} = 0.94.\n$$\nCompute the numerator and denominator:\n$$\n\\text{num} = 0.06 \\times 31.5 + \\sqrt{(0.06 \\times 31.5)^{2} + 4 \\times 0.94 \\times 0.06 \\times 45},\n$$\n$$\n\\text{den} = 2 \\times 0.94.\n$$\nNumerically,\n$$\n0.06 \\times 31.5 = 1.89,\\quad (1.89)^{2} = 3.5721,\\quad 4 \\times 0.94 \\times 0.06 \\times 45 = 10.152,\n$$\n$$\n\\sqrt{3.5721 + 10.152} = \\sqrt{13.7241} \\approx 3.70460,\n$$\n$$\n\\text{num} \\approx 1.89 + 3.70460 = 5.59460,\\quad \\text{den} = 1.88,\n$$\n$$\nC \\approx \\frac{5.59460}{1.88} \\approx 2.97585\\,\\mathrm{nM}.\n$$\nRounded to three significant figures, $C \\approx 2.98\\,\\mathrm{nM}$.\n\nAs a consistency check, compute the occupancies at this $C$:\n$$\n\\theta_A = \\frac{C}{K_{D,A} + C} \\approx \\frac{2.976}{1.5 + 2.976} \\approx \\frac{2.976}{4.476} \\approx 0.665,\n$$\n$$\n\\theta_B = \\frac{C}{K_{D,B} + C} \\approx \\frac{2.976}{30 + 2.976} \\approx \\frac{2.976}{32.976} \\approx 0.0902,\n$$\n$$\n\\theta_A \\theta_B \\approx 0.665 \\times 0.0902 \\approx 0.0600,\n$$\nwhich matches the target $P_{0} = 0.06$ within rounding.\n\nInterpretation regarding differential occupancy: within this independent-arm model, the bridging probability is the product $P_{\\text{bridge}}(C) = \\theta_A(C)\\theta_B(C)$. Consequently, it is strongly constrained by the lower of the two occupancies. At low concentrations $C \\ll K_{D,A}, K_{D,B}$, one has the approximation\n$$\n\\theta_i(C) \\approx \\frac{C}{K_{D,i}},\\quad P_{\\text{bridge}}(C) \\approx \\frac{C^{2}}{K_{D,A}K_{D,B}},\n$$\nso the weaker binder (larger $K_{D,i}$) disproportionately suppresses bridging via the product $K_{D,A}K_{D,B}$. As $C$ increases toward and beyond the smaller $K_{D,i}$, the corresponding arm saturates, but the overall $P_{\\text{bridge}}$ remains limited by the lagging arm with the larger $K_{D,i}$ until it, too, approaches saturation. Thus, differential occupancy compresses $P_{\\text{bridge}}$ toward the occupancy of the weaker arm, emphasizing that engineering more balanced affinities (or improving the weaker arm) can substantially increase the achievable bridging probability at a given $C$.", "answer": "$$\\boxed{2.98}$$", "id": "5012130"}, {"introduction": "Maximizing therapeutic efficacy while minimizing side effects is the central goal of drug design. This exercise explores a sophisticated safety strategy known as conditional binding, where a bispecific antibody is engineered to be preferentially active in the unique physiological conditions of a tumor. You will quantify the effectiveness of a pH-sensitive design by calculating its binding selectivity for the acidic tumor microenvironment versus the neutral pH of the bloodstream [@problem_id:5012137], providing a clear example of how to engineer a safer, more targeted biologic.", "problem": "A bispecific antibody engineered for conditional binding uses a pH-dependent arm to preferentially engage an antigen in the acidic tumor microenvironment while minimizing binding in the neutral bloodstream. Consider a single epitope recognized by this arm under the following conditions: the tumor interstitial pH is approximately $6.0$ and the blood pH is approximately $7.4$. The pH-dependent arm exhibits a dissociation constant ($K_D$) of $K_{D,\\text{pH}6} = 10$ nM at pH $6.0$ and $K_{D,\\text{pH}7.4} = 1\\,\\mu\\text{M}$ at pH $7.4$. Assume reversible $1{:}1$ binding, well-mixed compartments, and that the free concentration of the pH-dependent arm is the same in tumor and blood at equilibrium and equal to a given value $C$ (the free concentration). Assume $C$ is expressed in nM for numerical consistency when combining with the given $K_{D}$ values.\n\nStarting only from the law of mass action at equilibrium and the definition of the dissociation constant, derive an analytic expression for the fold-selectivity $S(C)$, defined as the ratio of the equilibrium fractional occupancy of the antigen in tumor (pH $6.0$) to that in blood (pH $7.4$), as a function of $C$. Express your final answer as a single closed-form expression for $S(C)$ in terms of $C$, with $C$ in nM. No rounding is required, and the final expression is unitless.", "solution": "The problem asks for an analytic expression for the fold-selectivity, $S(C)$, of a pH-dependent antibody arm. This selectivity is defined as the ratio of the fractional occupancy of an antigen in the tumor microenvironment to that in the blood. The derivation must start from the law of mass action.\n\nLet $A$ represent the antigen epitope, $B$ represent the free binding arm of the antibody, and $AB$ represent the antigen-antibody complex. The system is described by a reversible $1{:}1$ binding equilibrium:\n$$ A + B \\rightleftharpoons AB $$\n\nAccording to the law of mass action, at equilibrium, the dissociation constant, $K_D$, is defined as the ratio of the product of the concentrations of the dissociated species to the concentration of the complex:\n$$ K_D = \\frac{[A][B]}{[AB]} $$\nwhere $[A]$, $[B]$, and $[AB]$ are the equilibrium concentrations of the free antigen, free antibody arm, and the complex, respectively.\n\nThe fractional occupancy, $\\theta$, of the antigen is the fraction of total antigen sites that are occupied by the antibody arm. It is defined as:\n$$ \\theta = \\frac{\\text{Concentration of bound antigen}}{\\text{Total concentration of antigen}} = \\frac{[AB]}{[A]_{\\text{total}}} $$\nThe total concentration of the antigen, $[A]_{\\text{total}}$, is the sum of the free and bound antigen concentrations:\n$$ [A]_{\\text{total}} = [A] + [AB] $$\nSubstituting this into the expression for $\\theta$:\n$$ \\theta = \\frac{[AB]}{[A] + [AB]} $$\nTo express $\\theta$ in terms of the free antibody arm concentration, $[B]$, and the dissociation constant, $K_D$, we first rearrange the definition of $K_D$ to solve for $[A]$:\n$$ [A] = \\frac{K_D [AB]}{[B]} $$\nNow, we substitute this expression for $[A]$ into the equation for $\\theta$:\n$$ \\theta = \\frac{[AB]}{\\left(\\frac{K_D [AB]}{[B]}\\right) + [AB]} $$\nAssuming $[AB] \\neq 0$, we can divide the numerator and the denominator by $[AB]$:\n$$ \\theta = \\frac{1}{\\frac{K_D}{[B]} + 1} $$\nMultiplying the numerator and denominator by $[B]$ gives the standard form of the Hill-Langmuir equation for $1{:}1$ binding:\n$$ \\theta = \\frac{[B]}{K_D + [B]} $$\nThe problem states that the free concentration of the pH-dependent arm, $[B]$, is equal to a given value $C$ in both the tumor and blood compartments. Therefore, we can write the fractional occupancy in each compartment as a function of $C$.\n\nIn the tumor microenvironment (pH $6.0$):\nThe dissociation constant is given as $K_{D,\\text{pH}6} = 10$ nM.\nThe fractional occupancy in the tumor, $\\theta_{\\text{tumor}}$, is:\n$$ \\theta_{\\text{tumor}}(C) = \\frac{C}{K_{D,\\text{pH}6} + C} $$\n\nIn the blood (pH $7.4$):\nThe dissociation constant is given as $K_{D,\\text{pH}7.4} = 1\\,\\mu\\text{M}$. To maintain unit consistency with $C$ and $K_{D,\\text{pH}6}$ (both in nM), we must convert this value:\n$$ K_{D,\\text{pH}7.4} = 1\\,\\mu\\text{M} = 1 \\times 10^3 \\text{ nM} = 1000 \\text{ nM} $$\nThe fractional occupancy in the blood, $\\theta_{\\text{blood}}$, is:\n$$ \\theta_{\\text{blood}}(C) = \\frac{C}{K_{D,\\text{pH}7.4} + C} $$\n\nThe fold-selectivity, $S(C)$, is defined as the ratio of these two occupancies:\n$$ S(C) = \\frac{\\theta_{\\text{tumor}}(C)}{\\theta_{\\text{blood}}(C)} $$\nSubstituting the derived expressions for $\\theta_{\\text{tumor}}(C)$ and $\\theta_{\\text{blood}}(C)$:\n$$ S(C) = \\frac{\\left( \\frac{C}{K_{D,\\text{pH}6} + C} \\right)}{\\left( \\frac{C}{K_{D,\\text{pH}7.4} + C} \\right)} $$\nAssuming $C  0$, the term $C$ in the numerators cancels, and the expression simplifies to:\n$$ S(C) = \\frac{K_{D,\\text{pH}7.4} + C}{K_{D,\\text{pH}6} + C} $$\nThis is the general analytic expression for the fold-selectivity as a function of the free antibody arm concentration $C$.\n\nFinally, we substitute the given numerical values for the dissociation constants into this expression, where $C$ is in units of nM:\n$K_{D,\\text{pH}6} = 10$\n$K_{D,\\text{pH}7.4} = 1000$\n\n$$ S(C) = \\frac{1000 + C}{10 + C} $$\nThis is the final closed-form expression for the fold-selectivity $S(C)$. The expression is unitless, as it is a ratio of two quantities with the same units (concentration).", "answer": "$$\\boxed{\\frac{1000 + C}{10 + C}}$$", "id": "5012137"}]}